Tag: our research

With our funding, researchers in Canada have found key features in different meningiomas that can help predict tumour response to the most common treatments.

Ribociclib – a drug already used to treat breast cancer – may help slow the growth of diffuse hemispheric glioma.

One of our first Junior Fellowship grant holders, Dr Tyler Miller, has opened his own research lab focused on developing immunotherapies to treat brain tumours.

The Ways Ahead project aims to find ways to support, and improve quality of life for those diagnosed with a lower-grade brain tumour. It also explores ways to help friends and family who are supporting those diagnosed.

We are pleased to announce the two researchers who have been awarded our latest Expanding Theories grant!

Research that we funded nearly 20 years ago laid the foundations for last week’s approval of dabrafenib and trametinib to treat childhood gliomas.

CAR-T cell therapy is a type of immunotherapy that may be promising for treating brain tumours. There is lots of research in this field across the globe and it may one day be used more widely to treat this devastating disease.

Peter Buckle is a patient advocate and has worked with several teams, including the ARISTOCRAT team to champion research and clinical trials.

Dr Veronica Rendo, a researcher funded by The Brain Tumour Charity, shared the findings of her work at the annual meeting of the Society for Neuro-Oncology.

We are pleased to announce that The Brain Tumour Charity has joined the Cancer Tech Accelerator 3.0 as a new funding partner!

Two of our funded researchers have won awards at the Society for Immunotherapy of Cancer (SITC) annual conference!

We are pleased to announce the two researchers who have been awarded the Junior Fellowship grant – the second award in our Future Leaders programme!

We are pleased to announce that we have awarded £4.5 million to three new, exciting research initiatives.

We’re proud to announce the latest recipients of our Future Leaders grants that’ve been awarded for their innovative new research projects.

Experts at The Everest Centre are delivering a cutting-edge program of scientific research to develop pioneering new treatments for children diagnosed with low-grade brain tumours, following major new funding from The Brain Tumour Charity.

Offering coaching to promote healthy lifestyles could help reduce severe fatigue for patients following brain tumour treatment, a clinical trial has found.

Modern molecular profiling of medulloblastomas recently highlighted a previously unrecognised treatment benefit in a major international clinical trial.

A major UK trial of cannabis-based drug Sativex in treating the most aggressive form of brain tumour is to launch at 15 NHS hospitals, following promising results from a phase I study in 27 patients.

Geneticists from Trinity College Dublin have discovered how a specific genetic mutation called H3K27M causes a devastating, incurable childhood cancer, known as diffuse midline glioma (DMG), and, in lab studies working with model cell types, successfully reverse its effects to slow cancer cell growth with a targeted drug.

If we can find a way to interrupt a cancer cell’s ability to keep dividing, we may have a key to stopping tumours growing. Researchers, Dr Wong and Dr Voon ,tells us about the discovery they made into a tumour’s ability to continuously divide.

Research we funded has added value to a clinical trial that started in 2004. Updated scientific techniques showed that some children with a medulloblastoma can safely be spared harmful treatments.

We hear from two clinical psychologists who are helping young people after their brain tumour treatments through our ACT NOW study.

The Brian Cross Memorial Trust will fund ‘Future Leader’ Dr Spencer Watson’s three year glioblastoma brain tumour research.

New ‘Tessa Jowell Centre of Excellence’ status recognises delivery of outstanding care and treatment by NHS staff in their efforts to provide above excellent patient care through a difficult time